Nicotine Withdrawal and Junk Food Intake: A Study

Mar.28.2022
Nicotine Withdrawal and Junk Food Intake: A Study
Nicotine withdrawal symptoms vary and peak after 1-3 days, but psychological effects can persist. Quitting smoking often leads to increased junk food cravings.

According to a report by foreign media on March 27, 2022, it is well known that the symptoms of nicotine withdrawal vary from person to person, with some struggling more than others. However, these symptoms generally peak in the first 1-3 days of quitting smoking and gradually decrease over the course of 3-4 weeks. After this time, nicotine should be completely eliminated from one's system, but psychological effects often continue to persist.

 

When nicotine enters the bloodstream, it activates the reward and pleasure pathways in the brain by increasing the levels of dopamine, a neurotransmitter responsible for feelings of well-being. It is known to affect areas in the brain that regulate breathing, memory (enhancing it), appetite, and heart rate. The brain quickly becomes addicted to this stimulating effect.

 

Additionally, smokers often turn to smoking when socializing with friends, feeling bored, or in need of a pick-me-up. Over time, this can cause the brain to associate smoking with pleasure, making it difficult to overcome psychological withdrawal symptoms even after overcoming physical nicotine withdrawal symptoms.

 

The physical symptoms of nicotine withdrawal.

 

When the nicotine receptors in the brain are suddenly deprived of nicotine, the release of dopamine decreases. This can naturally lead to an uncomfortable sensation and a strong craving for smoking, as the body has become accustomed to the need for dopamine release. The craving for nicotine can last for 5 to 30 minutes, can be very uncomfortable, and will only subside over time or with the use of nicotine replacement therapy (NRT).

 

A recent study titled "Quitting Smoking Increases Junk Food Intake: The Role of Endogenous Opioid System" has been published in the Journal of Drug and Alcohol Dependence. The lead author of the study, Dr. Mustafa al'Absi, is a licensed psychologist and professor in the Department of Family Medicine and Bio-behavioral Health at the University of Minnesota Medical School. His team researched the brain functions responsible for addiction and appetite regulation, specifically examining the potential preference for junk food during nicotine withdrawal.

 

Researchers studied a group of smoking and non-smoking participants between the ages of 18 and 75. They were randomly assigned to quit using nicotine products for 24 hours and given either a placebo or 50mg of naltrexone. At the end of each session, participants were given snacks with varying calorie levels, salt, sugar, and fat content.

 

As expected, a research group has found that participants who quit smoking tend to choose foods that are high in calories, salt, fat, and sugar. The study observed the involvement of receptors in the brain's opioid system in this behavior. The study shows that food choices and consumption are influenced by smoking status (abstinence > occasional smokers or non-smokers; p < .05), opioid antagonists (naltrexone < placebo; p < .05), and gender (males > females; p < .05). These effects were confirmed for high-sugar and high-fat foods, but no differences were found in low-sugar and low-fat foods.

 

Researchers have concluded that the use of food, particularly high-calorie food, is often employed as a coping mechanism for the negative effects and discomfort experienced by individuals during the process of quitting smoking.

 

(Source: Vaping Post)

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
The U.S. Food and Drug Administration authorized 11 ZYN ULTRA nicotine pouch products made by Swedish Match USA through the premarket tobacco product application pathway on August 21, 2026. Ten of the authorized products have a labeled nicotine content of 9 mg, while ZYN ULTRA Smooth was authorized at 11 mg. The reviews were conducted through FDA’s nicotine pouch PMTA pilot program. FDA has now authorized 43 nicotine pouch products, including 23 through the pilot.
Aug.24
Former ATF Official’s Claims on Chinese Vape Companies and 6-Methyl Nicotine Fuel US Regulatory Debate
Former ATF Official’s Claims on Chinese Vape Companies and 6-Methyl Nicotine Fuel US Regulatory Debate
Former ATF Deputy Director Edgar Domenech has warned that some Chinese vape companies may be using 6-methyl nicotine, a nicotine analogue, raising new questions over how US regulators should classify emerging nicotine compounds.
Jul.13
From Nicotine Salts to Cocrystals: China’s Shenzhen Huabao institute explores a more stable form for sustained nicotine release
From Nicotine Salts to Cocrystals: China’s Shenzhen Huabao institute explores a more stable form for sustained nicotine release
China-based Shenzhen Huabao Collaborative Innovation Technology Research Institute Co., Ltd. has filed a patent application for a nicotine-ascorbic acid cocrystal, exploring a new solid-state form of nicotine. The patent proposes applications across e-liquids, heated tobacco sticks, oral tobacco, chewing tobacco and snuff. In nicotine pouch tests disclosed in the filing, cocrystal formulations showed less than a 6% decline in nicotine content after three months of accelerated storage and a release profile combining early-stage release with sustained delivery over 60 minutes. The filing reflects exploration of nicotine forms beyond conventional nicotine base and nicotine salts.
Aug.13
Kaival Brands Explores Nicotine Pouches as Smaller Nicotine Companies Seek Smoke-Free Growth
Kaival Brands Explores Nicotine Pouches as Smaller Nicotine Companies Seek Smoke-Free Growth
U.S. nicotine company Kaival Brands Innovations Group is exploring opportunities in nicotine pouches and other modern nicotine products, reflecting a broader shift among smaller nicotine businesses beyond traditional vaping products.
Jul.17
2Firsts Data | China’s Vape-Related Exports Rise 16.5% in July 2026 as U.S.-Bound Shipments Jump 53.5%
2Firsts Data | China’s Vape-Related Exports Rise 16.5% in July 2026 as U.S.-Bound Shipments Jump 53.5%
China’s vape-related exports reached $1.047 billion in July 2026, up 16.5% year on year and the highest monthly total of the year. Growth was heavily concentrated in the U.S., where exports jumped 53.5% to $404 million and accounted for 94.9% of the overall increase. Exports to all other markets rose just 1.2%. By category, nicotine-containing non-combustible products—primarily vapes—under HS24041200 rose 24.7% and generated 95.5% of the total increase. Vape-device exports under HS85434000 fell 0.4%, while other nicotine-substitute products under HS24041990 grew 88.9% but remained comparatively small.
DATA
Aug.24
 PMI Opens Generative AI Center in Portugal to Support Global Operations
PMI Opens Generative AI Center in Portugal to Support Global Operations
According to information released by Portugal’s Trade & Investment Agency (AICEP) in July 2026, Philip Morris International (PMI) has established a global Generative Artificial Intelligence Factory (GenAI Factory) at its Portuguese subsidiary Tabaqueira. The center will support PMI’s global operations by developing and deploying AI solutions focused on industrial process optimization, data analytics, operational automation and AI application development. The initiative strengthens Portugal’s role in PMI’s global technology and innovation network.
Aug.27